The Center has received doses of Corbevax, the COVID-19 vaccine developed by Biological E. Ltd. (BE), totaling 10 crore (100 million), the company reported on Thursday. The city-based vaccine manufacturer stated in a release: “Biological E. Limited has delivered 10 crore doses of Corbevax to the Government of India till now. PanIndia roll-out of Corbevax in children 12-14 years of age was initiated on March 16, 2022 and till now almost seven crore doses have been administered and 2.9 crore children have completed the two-dose vaccination regimen.”
The Union Health Ministry also gave Corbevax approval as a heterologous COVID-19 booster dosage under emergency use authorization for people 18 years of age and older after primary immunisation (two doses) with Covaxin or Covishield, the company reported. The COVID-19 Working Group of the National Technical Advisory Group (NTAGI) on Immunization’s recent recommendations served as the foundation for the Health Ministry’s approval.
From August 12, 2022, Corbevax is anticipated to be offered as a booster dosage through the CoWIN App in public and private vaccination centers. The vaccine was previously given the go-ahead for emergency use as a heterologous COVID-19 booster dosage for those age 18 and over on June 4, 2022, by the Drug Controller General of India (DCGI).
In a series of approvals from December 2021 to April 2022, the vaccine had gained emergency use authorisation as the primary two-dose immunisation schedule in adults, adolescents, and children aged five and above. For private COVID-19 vaccination centers, Corbevax is available for Rs. 250, GST inclusive. The price was set at Rs 400 for the consumer, including taxes and administrative expenses.